Stay current on changes and developments in corporate law with a wide variety of resources and tools.
May 20 — Chelsea Therapeutics International Ltd. directors didn't act in bad faith by instructing financial advisers to ignore certain projections when evaluating the company's sale to H. Lundbeck A/S, the Delaware Chancery Court ruled May 20.
Vice Chancellor Sam Glasscock III found it was reasonable for the board not to use “highly speculative projections” to value the company.
The projections predicted that the pharmaceutical company's value would increase in the future if the Food and Drug Administration approved its Northea product—a drug that treats a rare disorder—for other uses, or removed a competing drug from the market.
“The Plaintiffs argue, and it is no doubt conceivable, that reasons exist which might have made it wise for the Board to include the Projections in the Company’s valuation,” Glasscock wrote. “This disagreement with the actions of the Board does not plead a case of bad faith, however.”
In 2014, Lundbeck purchased Chelsea for $6.44 per share. The deal included contingent value rights (CVRs) worth up to $1.50, for a total possible consideration of $7.94 per share.
The plaintiffs alleged the transaction undervalued the company by between $266 million and $558 million. However, the court was skeptical of this valuation.
“The Defendants argue, and I agree, that if the Projections were a realistic indication that the Company’s value was hundreds of millions of dollar higher than Lundbeck’s offer, another bidder likely would have emerged throughout the 20-month long sales process,” Glasscock wrote.
Glasscock also noted the difficulty of shareholders bringing “catch-all” claims that disinterested, independent directors acted in bad faith.
“Thus conceived, bad faith is similar to the much older fiduciary prohibition of waste, and like waste, is a rara avis,” Glasscock said. “This matter involves the Plaintiffs’ unsuccessful pursuit of that rare bird.”
To contact the reporter on this story: Michael Greene in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Yin Wilczek at email@example.com
The opinion is available at http://src.bna.com/fcc.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)